RYBP

Across TCGA pan-cancer cohorts, RYBP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RYBP data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RYBP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RYBP expression acts as an unfavorable survival marker.

BRCA, SCLC, and BLCA are the cancer types where RYBP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.228	0.903	<.001	30	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
BLCA	OS	Median	All	0.228	0.720	.010	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RYBP–BRCA (DFS)

Open the BRCA breakdown →